We used a double labeling technique to search for molecular defects in two fibroblast strains obtained from patients with Pompe's disease. Analysis of the double labeled subcellular fractions by sodium dodecyl sulfate (SDS) electrophoresis did not reveal any abnormalities except in the "mitochondrial-lysosomal" fraction. In this fraction ratio deviations indicated that in Pompe's disease there was a significant decrease in counts of a protein with molecular weight of about 29,000. After solubilization by freezethawing this protein was shown to have an isoelectric point of 7.9 in contrast to the a-glucosidase which focused at about pH 4.7.
Summary
We used a double labeling technique to search for molecular defects in two fibroblast strains obtained from patients with Pompe's disease. Analysis of the double labeled subcellular fractions by sodium dodecyl sulfate (SDS) electrophoresis did not reveal any abnormalities except in the "mitochondrial-lysosomal" fraction. In this fraction ratio deviations indicated that in Pompe's disease there was a significant decrease in counts of a protein with molecular weight of about 29,000. After solubilization by freezethawing this protein was shown to have an isoelectric point of 7.9 in contrast to the a-glucosidase which focused at about pH 4.7.
Two-stage gel studies demonstrated an estimated !W% reduction of this protein in Pompe's disease. Two-stage studies of acid aglucosidase did not show any abnormal ratios of leucine incorporation. Similar although quantitatively less pronounced results were obtained in the study of skin fibroblasts from a patient with adult glycogen storage disease type 11.
MATERIALS A N D METHODS
Human skin fibroblast strains GM103, GM495 (normal control subjects), GM248 (Pompe's disease), and GM443 (adult GSD 11) were obtained from the Institute for Medical Research, Camden, NJ, and strains McH12 (normal control subject) and WG482 (Pompe's disease patient) were obtained from the Repository for Mutant Human Cell Strains, Montreal, Quebec. The procedures used for cell culturing and labeling, cell fractionation, polyacrylamide gel electrophoresis in the presence of sodium dodecyl sulfate (SDS-PAGE), isoelectric focusing (IEF), assay of radioactivity in gels, and analysis and plotting of data have been described in detail elsewhere (14) . a-l,4-Gluc0sidase was assayed in fibroblast lysates with 4-methylumbelliferyl-a-glucopyranoside (Sigma) as substrate by the method of Fujimoto et al. (5) . Staining for the enzyme in IEF gels was done according to the method of Salafsky and Nadler (17) . Protein was assayed by the method of Lowry et al.
(1 1) with bovine serum albumin as standard.
Speculation

RESULTS
The deficient basic protein with minimum molecular weight of 29,000 is structurally unrelated to acid glucosidase and represents a-GLUCOSIDASE ASSAYS a "new" molecular defect in type I1 glycogenosis.
To test whether the strains obtained from the cell repositories were indeed deficient in acid a-glucosidase activity the enzyme was assayed in lysates. Fibroblast strains from patients with Pom~e's disease3 lrnown as glycogen 'lorage disease type ' I Pompe's disease (GM248, WG482) had close to zero activity while (GSD 11) was first described in 1932 (I5). The disease the cell strain obtained from an adult GSD 11 patient (GM443) is characterized generalked glycogen showed approximately 25% residual activity of a-glucosidase. as hepatomegaly, profound hypotonia and massive enlargement of the heart with failure. In its typical infantile form Pompe's disease is uniformly lethal in the first year of life. In 1963 Hers (7) MACROMOLECULAR MAPPING demonstrated very reduced activity of lysosomal acid a-glucosi-SDS-PAGE of double labeled subcellular fractions of normal dase (acid maltase, EC 3.2.1.20) in the tissues of affected infants. control and Pompe's disease fibroblasts did not reveal any anomMore recently several groups have described milder forms of acid alies except in the "mitochondrial-lysosomal" (ML) fraction, a-glucosidase deficiency constituting the so-called late infantile, where there was indication of a molecular abnormality in a minor juvenile (childhood), and adult forms of GSD I1 (4, 8, 9) . In the protein peak with an apparent molecular weight of approximately adult form clinical manifestations are generally restricted to mus-29,000. When the ML fraction was submitted to repeated cycles cle weakness, often producing a picture similar to limb-girdle of freezing and thawing the "defect" was found in the solubilized muscular dystrophy (3).
(ML-S) portion (Fig. 1) . The particulate localization of this defecWe considered Pompe's disease a good model for testing our tive fraction, its solubilization by freezing and thawing, and the double labeling procedure (14) because a basic biochemical defect molecular weight of approximately 29,000 (the subunit molecular is known (acid a-glucosidase deficiency) and the disease is ex-weight for the bovine liver acid glucosidase is approximately pressed in cultured skin fibroblasts (8) . Moreover, acid maltase 26,000 (2)) were all compatible with the possibility that the "dehas lysosomal localization and its isoelectric point (18) and mo-fective" protein was acid maltase. However, analysis by IEF lecular weight (1, 18) are known although there are still questions showed an abnormal ratio at approximately pI 7.9 rather than at as to the structure of the human enzyme (1). However, when we pI 4.7 where the acid glucosidase could be detected by enzymatic began these studies we were unaware that many authors have staining. No glucosidase activity (acid or neutral) could be dequestioned, based on pathological and biochemical observations, tected at PI 7.9 in patients or control subjects. The abnormal ratios whether this enzyme is the single or primary genetic defect in were reproducible both by "inverting" the labels and using another GSD I1 (6, 10, 16, 19).
control strain (Fig. 2 ) and by using a second fibroblast strain from 894 DOUBLE LABELING TECHNIQUE IN MOLECULAR DEFECTS. 11. another patient with Pompe's disease. It remained to be proven that the "defective" regions in SDS-PAGE and IEF were due to the same protein fraction. Two-stage mapping performed by doing SDS-PAGE of the abnormal fraction from a n IEF gel showed a single peak again with a n apparent molecular weight of 29,000 in which there was a marked decrease in the label associated with Pompe's disease (Fig. 3a) . If the high "baseline" observed in this plot is averaged and subtracted, roughly a 90% reduction of label in Pompe's disease can be estimated by integrating the area under the peaks. In contrast, SDS-PAGE of the acid glucosidase band from IEF did not reveal any obvious abnormality (Fig. 36) . It was concluded that a basic protein fraction with minimum molecular weight of 29,000 was markedly deficient in infantile cases of G S D
T o test whether this deficiency is a general feature of G S D I1
and not a n exclusive feature of infantile cases, strain GM443 (adult GSDII) was studied. IEF of the double labeled ML-S 
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fraction again showed deficiency of a basic protein (Fig. 4) . Second stage analysis of this "defect" showed a decrease of a 29,000 molecular weight component in GSD I1 (Fig. 5a) . The decrease in label was smaller than the one seen in the infantile cases. SDS-PAGE of the acid glucosidase region from IEF again showed no abnormalities (Fig. 56) .
DISCUSSION
The delineated deficiency of a basic protein fraction with minimum apparent molecular weight of approximately 29,000 in Pompe's disease cannot be readily explained. Noteworthy is the fact that by using the double labeling technique a molecular defect with the characteristics of a-glucosidase could not be detected, even in two-stage mapping. This suggests that either a type I1 error (14) is being made (missing the defect) or that the acid maltase molecules of GSD I1 patients do not differ much in turnover, charge, or molecular weight from the normal enzyme. The fact that the "defect" observed in the basic protein fraction was caused by a deficiency of label associated with Pompe's disease rather than an excess rules out the possibility that it was caused by an acid maltase with altered isoelectric point.
Logically, if two correlated observations, say A and B, have been made, one of the following four situations must prevail: 1) A = B; 2) a third event C, causes both A and B; 3) A causes B; 4) B causes A. In three fibroblast strains from patients with GSD I1 two observations have been made: deficient acid rnaltase activity (A) and deficiency of a basic protein fraction (B). We will analyze these observations in the light of the above four alternatives: 1) A = B. A structural model might be envisaged in which native acid glucosidase was partially dissociated into its component units during IEF. In this case the basic component might represent an acid maltase subunit. This model is not in agreement with current knowledge of acid maltase structure, mainly because the dissociation of the enzyme occurs only in the presence of strong chaotropic agents; moreover, the enzyme subunits are insoluble in aqueous buffers (1,2). However, it would be desirable to check the deficient basic protein fraction for cross-reactivity with antiglucosidase antibodies.
2) C causes both A and B. In this case neither acid maltase deficiency nor the molecular defect delineated here would be the primary defect in Pompe's disease, but merely secondary to a third defect which might interfere with their "realization" (13) . Alternatively, and less likely, a regulatory gene mutation might be envisaged in Pompe's disease determining the deficiency of two different proteins.
3) A causes B. It might also be that events secondary to acid glucosidase deficiency, e.g., glycogen accumulation, lysosomal proliferation, etc., could possibly lead to decreased synthesis or increased degradation of other protein components, such as the one described.
4) B causes A. Finally, the reverse of the previous alternative might occur, i.e., the deficient basic protein described above might be the primary defect and secondarily lead to deficiency of acid glucosidase activity. Such might occur, for instance, if the deficient protein were an activator of acid rnaltase. Protein activators have been described for different lysosomal sphingolipid hydrolases (12) . Preliminary experiments involving mixing fibroblast lysates 
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PENA ET AL from normal control subjects and patients with Pompe's disease have already been performed in our laboratory but, so far, no latent acid maltase activity has been detected in Pompe's disease.
CONCLUSION
No final conclusion can be reached yet on the significance of the reported findings. However, the point should be made that by using a double labeling technique we have been able to define a discrete molecular abnormality, apparently structurally unrelated to acid glucosidase, in a particulate fraction of s k i fibroblasts from patients with Pompe's disease. This abnormality may r e p resent a "new" molecular defect in Pompe's disease. It was expressed as a significant ratio deviation that fits all previously defined criteria for abnormality (14) : the abnormal ratio corresponds to a discrete peak in SDS-PAGE and IEF gels; it was observed in three GSD I1 fibroblast strains, and it persisted when the labels were reversed. We feel that these findings are evidence of the usefulness of the double labeling technique in the investigation of the molecular pathology of inherited diseases, particularly of its ability to uncover unsuspected anomalies.
